Karyopharm TherapeuticsKPTI -2.46%52 Days Payable is 280.94 as of Mar. 2026, which is 1% above its 10-year median of 279.47. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.39 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 704 Biotechnology companies, Karyopharm Therapeutics ranks better than 68.47% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Karyopharm Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Karyopharm Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (KPTI) has a Days Payable of 280.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Karyopharm Therapeutics and its competitors. This is near median its historical median of 279.47. Over the past decade, Karyopharm Therapeutics' Days Payable has ranged from 153.20 to 403.14. According to the industry distribution chart, Karyopharm Therapeutics ranks #222 out of 704 companies in the Biotechnology industry, placing it in the top 31.5%.
Is Karyopharm Therapeutics' Days Payable too high?
Karyopharm Therapeutics' current Days Payable of 280.94 is near median its 10-year median of 279.47. Over the past 10 years, this metric has ranged from a low of 153.20 to a high of 403.14. The Biotechnology industry median Days Payable is 113.56. Karyopharm Therapeutics' value of 280.94 is 147.4% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #222 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Days Payable compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #222 out of 704 companies for Days Payable. This puts Karyopharm Therapeutics in the upper half of its industry. The industry median Days Payable is 113.56. Karyopharm Therapeutics' value of 280.94 is 147.4% above this benchmark. Historically, Karyopharm Therapeutics' own Days Payable has ranged from 153.20 to 403.14 over the past decade. While the company's 10-year median is 279.47 vs. the industry median of 113.56, Karyopharm Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current Days Payable of 280.94 is 147.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Days Payable is 280.94, which is near median its own 10-year median of 279.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.52 — trading 48.9% above its estimated fair value. The current Days Payable is 280.94, which is near median its 10-year median of 279.47 and 147.4% above the Biotechnology industry median of 113.56. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Days Payable is 280.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of $9.52 is trading 48.9% above its estimated GF Value™ of $6.39.
GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.
Key valuation signals for KPTI:
Days Payable: 280.94 (near median its 10-year median of 279.47)
GF Value™: $6.39 vs. price of $9.52 (48.9% above fair value)
Industry Position: 147.4% above the Biotechnology median (#222 of 704)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score
Get the complete analysis for KPTI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
